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The purpose of the present study was to evaluate the permeation profiles of unlabeled corticosterone (CS) drug from gels and adhesive patches as transdermal delivery systems. The effect of polyvinylpyrrolidone and certain chemical enhancers octylpyrrolidone (OP) and dodecylpyrrolidone (DDP) on the flux of drug through hairless mouse skin was also studied. The results show that presence of solubilizing agents such as hydroxypropyl-beta-cyclodextrin (HP--CD) decreased the drug flux from hydroxypropyl methylcellulose (HPMC) gel dermal base and controlled the diffusion kinetics. Increasing the drug thermodynamic activity by its autoclaving with 0.25% polyvinylpyrrolidone (PVP) (supersaturation) improved the drug flux through the skin by 3 fold from HPMC gel base dermal preparations. The results also reveal that chemical enhancer/HP--CD mixtures represent a suitable combination for controlling the release as well as increasing the flux of drug through skin. The addition of 5% HP--CD to OP solution not only increased the drug flux but also showed a controlled release that approached the zero order. Use of the chemical enhancer DDP in presence of HP--CD

INTRODUCTION
Transdermal delivery systems provide self-drug administration and their removal provokes an immediate reduction in the plasma level of the drug. Such system was applicable for the production of sustained and controllable levels of drug in the plasma, avoiding peaks and troughs reached with the oral or intravenous routes of administration, and thus, decreasing the risk of potential side effects. Drugs are applied to skin that act as an effective barrier to passage of substances into and out of the body for a local or systemic effect. The extent and rate of percutaneous drug absorption and transportation are influenced by skin physiology, physiochemical properties of drugs and excipients and design of delivery systems. 1 Mehta, 2 revealed the advantages of transdermal delivery systems and percutaneous route for systemic drug delivery. Skin is made up of several layers including stratum corneum, viable epidermis and dermis, and it contains appendages that include sweat glands, sebaceous gland and hair follicles. The outermost layer stratum corneum is the ratelimiting barrier to percutaneous drug transport. Such layer is a remarkably more effective barrier to drug transport than the epithelial barriers of gastrointestinal, nasal, buccal, vaginal or rectal routes. 3 Gel formulations generally provide faster drug release compared with ointments and creams in terms of use and patient acceptability. 2 Some drugs that have properties to penetrate the skin and are potent enough to be effective at low doses can be delivered transdermal gel. The combinations of polymer matrices and bioactive agents chosen must allow for the drug to diffuse through the pores or macromolecular structure of the polymer upon introduction of the delivery system into the biological environment without including any change in the polymer itself. 4 Most transdermal patches are designed to release the active ingredient at a zero-order rate for a period of several hours to days following application to skin. This is especially advantageous for prophylactic treatment or maintenance therapy in chronic conditions where the patient is required to carry around oral medications and remember to take them several times a day. The following investigation was carried out to determine the effect of polyvinylpyrrolidone as well as the two chemical enhancers octyl-and dodecyl pyrrolidones on flux of corticosterone from gel and adhesive patch as models of topical preparations.
EXPERIMENTAL
Materials
Unlabeled 
B) Preparation of 3H-CS transdermal
patches 40 μl of the radioactive drug previously dissolved in ethanol was added to 5 ml of the adhesive solution (acrylic polymer either 387-2516 or 387-2287 dissolved in mixture of ethanol, methanol and ethyl acetate, as received from the supplier) for each individual preparation in special mold lined with aluminum foil. In some formulations octylpyrrolidone was included in a concentration of 5 % v/v of the preparation. The mixture was then stirred carefully to avoid the introduction of air bubbles, covered and left for 4 days to allow complete evaporation of the solvent. The product was 1.5 -cm diameter aluminumbacked adhesive film of 1-mm thickness that loaded with 40 μl 3 H-CS.
Drug content
The exact 3 H-CS content of the gel and individual patches was determined after appropriate dissolution of 2 gms gel base and the individual patches in 50-methanol. 10 μl of methanol solution was diluted with 10 ml cocktail and the 3 H-CS content of both formulations was measured by liquid scintillation counter.
In-vitro Permeation of 3H-CS from transdermal systems a) From gel formulation
The in-vitro permeation profile of H-CS was evenly spread on the skin membrane in the donor chamber. The receiver compartment had a volume of 20 ml of PBS. The cell was kept at 37° with stirring of the receiver phase at 300 rpm. Sampling arms and donor apertures were occluded with Para-film. For each formula, the permeation profile of 3 H-CS was followed for 6 hours. At time intervals (1 hr each), 1000 μL aliquots from the receiver chamber were taken, mixed with scintillation cocktail and analyzed with a liquid scintillation counter. The sample taken was replaced by the same volume of fresh PBS that added to receiver chamber to maintain a constant solution.
b) From patches
The adhesive/drug films were firmly pressed onto the center of abdominal hairless mouse skin specimen. Once adhesion to the skin surface had been confirmed the skin was quickly mounted on the flange of Franz-type diffusion cell receptor compartment such that the patch was situated precisely over the flange aperture. The donor compartment was then placed in position and the two halves of the cell sealed together with Para-film. For each transdermal patch, the permeation profile of 3 H-CS was determined for 12 hours following the same procedure described under gel.
RESULTS AND DISCUSSION
In-vitro flux of corticosterone from transdermal delivery systems A) From gel formulation
The results of in-vitro permeation profiles of 3 H-CS from gel formulations through hairless mouse skin are presented in Figures (1-3 ) and the drug release behavior was analyzed in terms of the main physico-chemical parameters of the systems examined. Figure 1 , presented the release profiles of 3 H-CS from the gel base saturated with CS in absence and in presence of 5% HP-β-CD through hairless mouse skin. The results show that presence of 5% HP-β-CD significantly decreased cumulative amounts of 3 H-CS (dpm, disintegration per time) released in the receiver chamber by about 10 fold. This effect was attributed to decrease of free 3 H-CS in the donor compartment as a result of complexation with cyclodextrin. 5 Also, it was obvious that the presence of 5% HP-β-CD gave a constant diffusive gradient suggesting that complexation controls the diffusion pattern of the drug.
The effect of Polyvinylpyrrolidone (PVP) is presented in Figure 2 , showing the release of supersaturated autoclaved CS solution in presence of 0.25% PVP. The cumulative amounts of M OP/ 5% HP-β-CD are presented in Figure  ( 3), showing that both concentrations increased the drug release from HPMC gel base. The results also revealed that addition of 5% HP-β-CD to 2.3 x 10 -2 M of OP solution not only increased the drug flux 10 times but also resulted in a controlled release behavior due to drug complexation with cyclodextrin. 5 This behavior is reflected by kinetics that approached to a zero order that ensures a controlled availability in-vivo. Such results are in agreement with the study of Orienti and others, 7 who reported that, the presence of complexing agents such as β-cyclodextrin in dermal bases controls the diffusion kinetics due to regulation of the amount of drug diffused through complexation. Bibby and others 8 
B) From patches
The chemical nature of a transdermal adhesive can affect the solubility of the drug. 9 Adhesives containing OH groups were found to produce homogenous and stable patches, possibly due to hydrogen bond formation that provided good rates of drug release. 3 H-CS was formulated as a monolithic adhesive matrix type patch. In the present study corticosterone patches were prepared using two types of polyacrylate polymers containing alcohol function groups; Duro-tak® 387-2516 and 387-2287, and the chemical permeation enhancer octyl-pyrrolidone was incorporated in the patches (1.5 cm diameter and 1-mm thickness).
The permeation profiles of 3 H-CS across hairless mouse skin in absence or in presence of OP from Duro-tak 2516® and Duro-tak® 2287 are presented in Figure 4 (A and B) . The profiles from both patches show an increase in the cumulative amounts of Table (1) . The data show that there is a difference between the two adhesives Duro-tak® 2516 and 2287® in terms of skin permeation. The rate of drug release from the former patch is 2 times greater than that from the later (the drug flux was 9.05 and 4.67x10 -9 from D-2516 and 2287 respectively). This result may be attributed to the cross-linked structure of Durotak® 2516 that may provide a more tortuous pathway for drug release than adhesive 2287®, which lacked cross-linking. Jeans and Heard 10 previously reported this difference in adhesives chemical structure. The results are also in agreement with that of Park and others. 11 They reported that incorporation of chemical permeation enhancers such as DMSO, oleic acid and lauryl alcohol in the transdermal patch was essential to increase the permeation rate of Captopril from transdermal patches. 
